



Virulence Induction in *Pseudomonas aeruginosa* under Inorganic Phosphate Limitation: a Proteomics Perspective

 Miguel A. Matilla,^a  Zulema Udaondo,^b  Sandra Maaß,^c Dörte Becher,^c  Tino Krell^a

^aDepartment of Biotechnology and Environmental Protection, Estación Experimental del Zaidín, Consejo Superior de Investigaciones Científicas, Granada, Spain

^bDepartment of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

^cDepartment of Microbial Proteomics, Institute of Microbiology, University of Greifswald, Greifswald, Germany

Miguel A. Matilla and Zulema Udaondo contributed equally to this work. The author order was determined alphabetically.

ABSTRACT Inorganic phosphate (Pi) is a central nutrient and signal molecule for bacteria. Pi limitation was shown to increase the virulence of several phylogenetically diverse pathogenic bacteria with different lifestyles. Hypophosphatemia enhances the risk of death in patients due to general bacteremia and was observed after surgical injury in humans. Phosphate therapy, or the reduction of bacterial virulence by the administration of Pi or phosphate-containing compounds, is a promising anti-infective therapy approach that will not cause cytotoxicity or the emergence of antibiotic-resistant strains. The proof of concept of phosphate therapy has been obtained using primarily *Pseudomonas aeruginosa* (PA). However, a detailed understanding of Pi-induced changes at protein levels is missing. Using pyocyanin production as proxy, we show that the Pi-mediated induction of virulence is a highly cooperative process that occurs between 0.2 to 0.6 mM Pi. We present a proteomics study of PA grown in minimal medium supplemented with either 0.2 mM or 1 mM Pi and rich medium. About half of the predicted PA proteins could be quantified. Among the 1,471 dysregulated proteins comparing growth in 0.2 mM to 1 mM Pi, 1,100 were depleted under Pi-deficient conditions. Most of these proteins are involved in general and energy metabolism, different biosynthetic and catabolic routes, or transport. Pi depletion caused accumulation of proteins that belong to all major families of virulence factors, including pyocyanin synthesis, secretion systems, quorum sensing, chemosensory signaling, and the secretion of proteases, phospholipases, and phosphatases, which correlated with an increase in exoenzyme production and antibacterial activity.

IMPORTANCE Antibiotics are our main weapons to fight pathogenic bacteria, but the increase in antibiotic-resistant strains and their consequences represents a major global health challenge, revealing the necessity to develop alternative antimicrobial strategies that do not involve the bacterial killing or growth inhibition. *P. aeruginosa* has been placed second on the global priority list to guide research on the development of new antibiotics. One of the most promising alternative strategies is the phosphate therapy for which the proof of concept has been obtained for *P. aeruginosa*. This article reports the detailed changes at the protein levels comparing *P. aeruginosa* grown under Pi-abundant and Pi-depleted conditions. These data describe in detail the molecular mechanisms underlying phosphate therapy. Apart from Pi, several other phosphate-containing compounds have been used for phosphate therapy and this study will serve as a reference for comparative studies aimed at evaluating the effect of alternative compounds.

KEYWORDS *Pseudomonas aeruginosa*, phosphate starvation, proteomics, anti-infective therapy, pyocyanin, quorum sensing, virulence

Editor Giordano Rampioni, University Roma Tre

Copyright © 2022 Matilla et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Miguel A. Matilla, miguel.matilla@eez.csic.es, or Tino Krell, tino.krell@eez.csic.es.

The authors declare no conflict of interest.

Received 7 July 2022

Accepted 20 October 2022

Published 10 November 2022

P*seudomonas aeruginosa* (PA) is among the most feared human pathogens. It is an opportunistic pathogen that frequently causes nosocomial disease by infecting debilitated patients. PA is omnipresent in the environment and has been detected in different soil, water, human and animal-derived samples, different foods like salads, vegetables, and milk, as well as in plumbing systems or hospital settings (1–3). PA is a highly versatile pathogen, able to infect almost all human tissues, including the respiratory tract, ear, eye, brain, heart, and urinary tract, and causes a general bacteremia (4). PA is of important clinical relevance since: (i) infections are associated with significant death rates; (ii) it is among the most frequent causes of nosocomial infections; and (iii) multidrug-resistant strains are rapidly emerging (5–8). In addition to humans, PA infects animals and plants (9, 10).

Phosphorous is an essential element for all living cells and required for the synthesis of ATP, nucleic acids, phospholipids, and other biomolecules. In addition to its metabolic importance, inorganic phosphate (Pi) is an important signal molecule that modulates virulence in many different pathogens, including human-pathogenic bacteria like *Vibrio cholerae* (11), *Bacillus anthracis* (12), *Mycobacterium tuberculosis* (13), *Staphylococcus aureus* (14), the bacterial phytopathogens *Agrobacterium tumefaciens* (15) and *Xanthomonas oryzae* (16), or the human fungal pathogen *Candida albicans* (17). In the context of PA, Pi starvation was found to elicit important transcriptional changes (18) that were shown to shift this bacterium toward virulent phenotypes (19–21). The role of Pi as a signal molecule that controls virulence is likely to be related to the low phosphate availability in a healthy person (1.25 mM) that then becomes limited in patients following chemotherapy or who have undergone a recent surgical intervention (<0.03 mM) (20–22).

Pi is sensed by a sophisticated signaling complex comprised by the PstABCS phosphate transporter that is linked through the coupling protein PhoU to the PhoRB two-component system. Under Pi-limiting conditions, the PhoR kinase phosphorylates its response regulator PhoB to regulate gene expression (23). Several studies show that Pi starvation causes a PhoRB-mediated activation of the Rhl and PQS quorum sensing (QS) systems, whereas the Las QS system is dispensable (24–26).

PA was found to be present in the intestine of 20% of healthy individuals and up to 50% of hospitalized patients (27). Furthermore, the intestinal tract was identified as the primary site from which PA spreads, causing sepsis (28). Surgical interventions were shown to deplete intestinal Pi, in turn causing an activation of bacterial virulence (20, 21). A mouse model was established in which surgical injury was induced followed by intestinal PA inoculation (21). Several studies showed that the oral administration of Pi prior to the surgical injury of mice protected the animals against infections caused by PA (21, 29) and *C. albicans* (30). This approach was termed phosphate therapy and subsequently optimized using different phosphate-containing polyethylene glycol (PEG) polymers combining the favorable properties of Pi and PEG (31–34) or the use of nanomaterials that release Pi (35). The administration of Pi-PEG polymers not only suppressed virulence in PA but also in *Serratia marcescens*, *Klebsiella oxytoca*, *Enterococcus faecalis*, *Klebsiella oxytoca*, *C. albicans* (31), and in multispecies communities isolated from the intestine (33). In addition, the application of polyphosphate also caused a reduction of *S. marcescens* and PA virulence treats (36). These data suggest a universal nature of phosphate therapy to fight different classes of pathogens.

The increase in antibiotic-resistant microorganisms and their consequences represents a major global health challenge. Antimicrobial-resistant infections kill 700,000 patients per year (37, 38) and estimations indicate that this toll will rise to 10 million deaths annually by 2050 (38). Due to several different reasons, the pipeline to develop novel antibiotics is drying out (39). The current situation is referred to as antibiotics resistance crisis (40) and the World Health Organization (WHO) warns that a postantibiotic era, in which common infection and minor injuries kill, is far from being an apocalyptic fantasy, but a real possibility (41). As a result, the WHO has rated the development of new antimicrobial agents as critical and has placed PA second on global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics (42). However, fighting antibiotic-

resistant bacteria with novel antibiotics will cause again the selection of resistant strains, resulting in a vicious cycle that may not permit to tackle antimicrobial resistance over the long term. Although there is a desperate need for the discovery of novel antibiotics, approaches like the phosphate therapy are promising alternatives to fight pathogenic microorganisms (43–46).

Comprehensive information on the changes at the protein level caused by Pi scarceness in PA is lacking. However, this information is essential to comprehend the molecular basis underlying phosphate therapy and it is the primary objective of this article to fill this gap in knowledge. We report here a proteomics study of PA grown in rich medium, or minimal medium supplemented with 0.2 mM or 1 mM Pi. About half of the predicted PA proteins could be quantified and vast changes at the protein level were detected comparing samples containing 0.2 mM and 1 mM Pi.

RESULTS AND DISCUSSION

Pyocyanin production is stimulated over a very narrow Pi window in a highly cooperative process. To determine the effect of different Pi concentrations on the regulation of virulence in PA, initial experiments were conducted to study the production of the virulence factor pyocyanin as a proxy. The canonical reference strain in PA research, PAO1, was used as a model. We conducted growth experiments in minimal medium (MM) supplemented with different Pi concentrations. Growth in the presence of 50 and 1 mM could be considered identical, whereas a slight reduction in the growth rate was observed in the presence of 0.2 mM Pi (Fig. 1A). This deviation was significantly larger at 0.1 mM Pi (Fig. 1A). The visual inspection of the Erlenmeyer flasks at the end of the growth experiment (Fig. 1B) revealed an intense blue-green color at 0.2 mM and 0.1 mM, indicative of an elevated pyocyanin production, whereas the cultures with 1 and 50 mM were pale. To precisely determine the Pi concentration range at which pyocyanin production was altered, we repeated growth experiments incrementing the Pi concentration in 0.1 mM steps and extracted pyocyanin (Fig. 1C) for its spectrometric quantification (Fig. 1D). Experiments showed that the transition occurs between 0.6 mM and 0.2 mM Pi. This 3-fold reduction in the Pi concentration caused about a 75-fold increase in the pyocyanin production (Fig. 1D), indicative of a regulatory mechanism characterized by very strong positive cooperativity.

Phosphate starvation stimulates exoenzyme production and antibacterial activity. Among the hallmarks of PA virulence is the increased production of extracellular invasive enzymes such as elastases and proteases (47). As shown in Fig. 2A, the elastase activity of cell-free supernatants of PA grown in the presence of 0.2 mM Pi was about 5-fold higher than supernatants derived from cultures in 1 mM Pi. Fig. 2B illustrates the proteolytic capacity of these cell-free supernatants on skim milk agar, which is illustrated by the appearance of a clearance area around the bacterial colony. In analogy to the elastase activity, the protease activity under Pi starvation was significantly increased. Dramatic changes were observed in the measurements of the antibacterial activity of these supernatants, as monitored by a bioassay to kill *Chromobacterium violaceum* cells forming a lawn on agar plates. The placement of supernatants of PA grown with 0.2 mM Pi into holes punched into the plate caused a very significant antibacterial halo, whereas no antibacterial activity was detected for supernatants derived from cultures grown with 1 mM Pi (Fig. 2C).

Reduction of Pi from 1 to 0.2 mM Pi causes large proteome changes. To get insight into the changes in the proteome caused by altered Pi levels, we prepared protein extracts from cultures grown in MM supplemented with 1 mM and 0.2 mM Pi as well as in LB rich medium. Samples were taken at an optical density at 660 nm (OD_{660}) of 0.6, which implies that the supernatant Pi concentration at the moment of sample taking for cultures grown in 1 mM and 0.2 mM Pi was of approximately 700 and 13 μ M, respectively (Fig. 1A). An SDS-PAGE gel of the three replicate samples used for proteomics is shown in Fig. 3. Whereas, visually the proteomes of PA grown in LB and MM + 1 mM Pi are similar, there are very important changes comparing samples grown in MM + 1 mM Pi and MM + 0.2 mM Pi (Fig. 3).




FIG 1 Growth of *P. aeruginosa* in the presence of different inorganic phosphate (Pi) concentrations. (A) Growth curves in minimal medium supplemented with different concentrations of Pi. The growth kinetics of cultures grown in 50 mM and 1 mM Pi are almost identical; hence the curve for 50 mM Pi has been omitted. The following growth rates were derived (in number of generations per h): 50 mM Pi, 1.01 ± 0.03 ; 1 mM Pi, 1.06 ± 0.03 ; 0.2 mM Pi, 0.87 ± 0.02 ; 0.1 mM Pi, 0.71 ± 0.02 . The Pi concentration in supernatants is also shown. Growth (open symbols), Pi consumption (filled symbols). (B) Erlenmeyer flasks containing PA cultures after culture for 24 h at 37°C. (C) Cell-free supernatants from PA cultures grown in the presence of different Pi concentrations. (D) Quantification of pyocyanin from supernatants shown in C. Data were normalized using the cell density.




FIG 2 Exoenzyme production and antibacterial activity of *P. aeruginosa* PAO1 under Pi-deficient (0.2 mM) and -sufficient (1 mM) conditions. (A) Elastase activity in *P. aeruginosa* PAO1 supernatants. Data were normalized for culture density (OD₆₆₀). Data are the means and standard deviations of three biological replicates. (B) Protease activity in *P. aeruginosa* PAO1 supernatants in skim milk agar plates. (C) Halos of antibiosis against *Chromobacterium violaceum* CV026 of filter-sterilized supernatants of *P. aeruginosa* PAO1. In B and C, the bioassays were conducted in triplicate and representative images are shown.

The proteomics analyses of these three conditions resulted in the quantification of a similar number of proteins, namely 2,716; 2,747; and 2,733 for the MM + 0.2 mM Pi, MM + 1 mM Pi, and LB samples, respectively (see Data Set S1 in the supplemental material). Considering that there are 5,587 annotated protein coding genes in the PA PAO1 genome (48), this corresponds to a coverage of about 49%. In this article, we analyze the changes in the proteome that occurred in cultures grown in the presence of 0.2 mM Pi compared to 1 mM Pi. Differentially abundant proteins are defined by a magnitude of the log₂ fold change superior to 0.8 as well as a *P* value inferior to 0.01 in a Student's *t* test comparing the two growth conditions. In total, 295 and 1,022 proteins were found to be enriched or depleted, respectively, comparing growth in 0.2 mM Pi to 1 mM Pi. In addition, there were several cases where a given protein was detected in the three replicates of one growth condition but was not identified in the three replicates from the other growth conditions. It is very likely that the failure to detect a given protein in one growth condition is due to its concentration being below the dynamic detection range of the mass spectrometer. These proteins were thus included into the lists of depleted (Data Set S2) and accumulated proteins (Data Set S3). Growth in 0.2 mM Pi compared to 1 mM Pi resulted primarily in the downregulation of protein abundance (1,100 proteins [Data Set S2]), and in an accumulation of 371 proteins (Data Set S3) (Table 1, Fig. 4).

Lower abundance of proteins involved in metabolism and biosynthesis during Pi limitation. The reduction in the Pi concentration resulted in lowered amounts of about 40% of the detected proteins that correspond to ~20% of the proteins encoded in the genome of PAO1 (Data Set S2). The 10 proteins with the strongest depletion are listed in Table 2 and include proteins involved in the general metabolism, like the maintenance of redox homeostasis or respiratory electron transfer chain, transport,




FIG 3 SDS-PAGE gel of protein extracts of *P. aeruginosa* cultures grown in LB rich medium or minimal medium supplemented with 1 mM or 0.2 mM Pi. Shown are the samples for three biological replicates that were used for the proteomics analysis. M, protein marker.

biosynthesis, and catabolism. Fig. 5 shows a map of PA metabolic processes in which the downregulated processes are highlighted in red and the classification of differentially abundant proteins according to the KEGG Orthology (KO terms) is shown in Fig. 6. Major downregulated processes include the glycolysis/gluconeogenesis and Krebs cycle, the glyoxylate cycle, the pentose phosphate metabolism, and the pathway for dissimilatory nitrate reduction. Importantly, biosynthetic pathways for many amino acids, phosphatidylethanolamine, inosine 5'-monophosphate, pyridoxal phosphate, Coenzyme A, UDP-*N*-acetyl-D-glucosamine, siroheme, polyamines, and glutathione were also downregulated (Fig. 5 and 6; Data Set S2). Furthermore, protein levels for several metabolic pathways were reduced, like those for different amino biosynthesis, and phosphonate and phosphinate metabolism. Several enzymes of the fatty acid biosynthesis and degradation as well as the Entner-Doudoroff pathways were depleted whereas others showed increased levels (Fig. 5 and 6). The reduction in the Pi level caused significantly lowered amounts of enzymes in the biosynthesis and metabolism of all major groups of biological molecules, like carbohydrates, lipids, amino acids, cofactors, and vitamins as well as secondary metabolites (Fig. 6). Next to the reduction in the abundance of proteins involved in the biosynthesis and metabolism of biomolecules, there were numerous proteins with decreased amounts that participate in energy metabolism as well as signal processing like transcriptional regulation. The fact that the primary consequence of the reduction in Pi from 1 mM to 0.2 mM is a reduction in abundance of 1,100 proteins is also reflected in a general depletion of ribosomal proteins. In total, 36 ribosomal proteins were detected at lower levels with an average magnitude of $2.51 \pm 0.98 \log_2$ fold change that corresponds to about a 6-fold mean reduction of ribosomal proteins under Pi-limiting conditions (Fig. 7).

Many accumulated proteins under Pi-limiting conditions participate in virulence processes. Among the proteins with the highest enrichment under Pi limitation (Table 2) were 5 proteins required for the synthesis of phenazine virulence factors (e.g., pyocyanin), 3 proteins involved in phosphate transport (OprO, OprP) and regulation (PhoB), a protein of a secretion system (PdtA), and two proteins of unknown function

TABLE 1 Proteins with altered abundance in *P. aeruginosa* grown in minimal medium plus 0.2 mM Pi compared to minimal medium plus 1 mM Pi

Sense of change	Detected in both conditions and statistically different	Not detectable in the 0.2 mM Pi samples, but detected in the 1 mM Pi samples	Detected in the 0.2 mM Pi samples, but not detected in the 1 mM Pi samples	Total
Enriched proteins	295		76	371
Depleted proteins	1,022	78		1,100




FIG 4 Heatmaps derived from *P. aeruginosa* growth in minimal medium supplemented with 0.2 mM or 1 mM Pi. (A) Protein abundance (intensity-based absolute quantification [iBAQ] values) in both samples. The gray shading indicates that the protein could not be detected in any of the three replicates of one condition, but was quantified in the three replicates of the other condition (referred to as “ON” or “OFF” at “low Pi” or “high Pi” in Data Set S2 and S3). (B) Log₂ fold changes (FC) for growth in 0.2 mM compared to 1 mM Pi.

that belong to the regulon of the VreRI extracytoplasmic function (ECF) sigma factor system that is active during infection, promoting transcription of potential virulence determinants (49). An analysis of the totality of accumulated proteins permits their classification into several categories (Table 3) that are mainly related to phosphate acquisition or virulence processes.

(i) Proteins related to phosphate and phosphonate transport and regulation. As mentioned above, the induction of pyocyanin production is a highly cooperative process (Fig. 1B–D). Pi is sensed by a complex comprising the PstABCS high-affinity phosphate transporter, the PhoU coupling protein and the PhoRB two-component system (50). The reduction in Pi in the growth medium resulted in a higher abundance of these proteins involved in Pi transport and sensing (Table 3; Data Set S3). OprP and OprO are outer membrane channels that permit the specific uptake of phosphate or pyrophosphate (51, 52) and under Pi starvation both proteins were found to be

TABLE 2 Proteins with largest changes in abundance after growth in minimal medium plus 0.2 mM Pi compared to minimal medium plus 1 mM Pi

Locus tag	Gene	Protein name	Protein function/comment	Log ₂ FC	Ref.
Depleted					
PA0196	<i>pntB</i>	Pyridine nucleotide transhydrogenase, beta subunit	Regulation of NAD(P) ⁺ /NAD(P)H redox homeostasis	-7.27	111
PA1680		Predicted 3-oxoadipate enol-lactonase activity	Predicted role in benzoate catabolism	-6.46	112
PA1555	<i>ccoP2</i>	Cytochrome c oxidase, cbb3-type, CcoP subunit	Respiratory electron transfer chain component	-6.36	
PA2840		ATP-dependent RNA helicase	Regulation of type 3 secretion system	-6.30	113
PA1297	<i>aitP</i>	Metal transporter	Fe ²⁺ and Co ²⁺ export	-6.18	114
PA3321		Transcriptional regulator		-6.10	
PA0141		Polyphosphate kinase	GTP synthesis	-6.06	115
PA5118	<i>thil</i>	Thiazole biosynthesis protein	Thiazole synthesis	-6.02	
PA1964		ATP-binding component of ABC transporter	Transport	-5.98	
PA4243	<i>secY</i>	Secretion protein SecY	Protein export	-5.93	
Enriched					
PA3330		Probable short-chain dehydrogenase	Regulated by quorum sensing	8.62	116
PA4214 ^a	<i>phzE₁</i>	Phenazine biosynthesis protein PhzE	Phenazine (pyocyanin) biosynthesis, host interaction	7.90	117
PA1903 ^a	<i>phzE₂</i>	Phenazine biosynthesis protein PhzE	Phenazine (pyocyanin) biosynthesis, host interaction	7.90	
PA4216 ^a	<i>phzG₁</i>	Probable pyridoxamine 5'-phosphate oxidase		7.33	
PA1905 ^a	<i>phzG₂</i>	Probable pyridoxamine 59-phosphate oxidase		7.33	
PA3280	<i>oprO</i>	Pyrophosphate-specific outer membrane porin OprO	Phosphate and diphosphate transport	6.45	51
PA3279	<i>oprP</i>	Phosphate-specific outer membrane porin OprP		6.36	
PA5360	<i>phoB</i>	Two-component response regulator PhoB	Transcriptional regulation in response to Pi starvation	6.33	118
PA4211	<i>phzB₁</i>	Phenazine biosynthesis protein	Phenazine biosynthesis	6.13	117
PA0690	<i>pdta</i>	Phosphate depletion regulated two-partner secretion system partner A	Secretion system involved in virulence	5.97	119
PA0696		Hypothetical protein	Unknown, part of the σ^{Vrel} regulon, upregulated by Pi	5.92	120, 121
PA0698		Hypothetical protein		5.80	

^aProteins of the same sequence.

enriched at similar levels, namely, by factors of 82- and 87-fold (Table 3), indicating that these vicinal genes are subject to similar regulatory processes. Transcript levels of *oprO* and *oprP* were found to be upregulated when PA makes contact with lung epithelial cells (53). Next to the higher abundance of the PstABCS phosphate transporter, two of the three subunits of the PhnCDE phosphonate transporter were also detected




FIG 5 Metabolic map summarizing the principal differences in the proteomes of *P. aeruginosa* grown in minimal medium in the presence of 0.2 mM and 1 mM Pi. Up- and downregulated routes are shown in blue and red, respectively. Routes that contain both depleted and enriched proteins are annotated in black. 1, Phosphate acetyltransferase-acetate kinase pathway; 2, glyoxylate cycle; 3, lysine degradation; 4, isoleucine biosynthesis; 5, arginine and proline metabolism; 6, dissimilatory nitrate reduction; 7, polyamine biosynthesis; 8, glutathione biosynthesis; 9, tyrosine biosynthesis; 10, phosphonate and phosphinate metabolism.




FIG 6 Analysis of differences in the proteomes of *P. aeruginosa* grown in the presence of 0.2 mM Pi compared to 1 mM. Classification of observed changes according to KEGG Orthology (KO) terms.

in larger amounts. Phosphonates are phosphorus-containing organic molecules in which the phosphorous atom is linked directly to a carbon atom in a stable chemical bond. However, studies of *E. coli* PhnCDE revealed that it also transports Pi and the authors conclude that PhnCDE has to be considered a genuine phosphate transporter (54).

(ii) Secretion systems. Protein secretion systems are multiprotein complexes that are used to release proteins, toxins, or enzymes, for example, enzymes that hydrolyze complex carbon sources or proteins that capture essential elements such as iron (55). These systems are also used to colonize and survive within eukaryotic hosts, causing acute or chronic infections, subverting the host cell response, and escaping the immune system (56). Pi limitation modulated protein levels of both type II and type VI secretion systems (Fig. 8, Table 3).

PA has two homologous type II secretion systems, Hxc and Xcp, and several proteins of both systems were among the enriched proteins under Pi limitation (Fig. 8, Table 3). This accumulation was accompanied by an increase in the levels of numerous proteins that were shown to be secreted by these systems (Fig. 8). Some of these proteins, namely, different phosphatases and phosphodiesterases, are involved in the Pi metabolism, whereas others were proteases and a chitin-binding protein (Table 3). Among the accumulated proteins that are secreted by the type II system is the protease LasA that is among the most relevant PA virulence factors. LasA acts synergistically with elastase LasB to degrade elastin (57). Elastin fibers are abundant in different human tissues like lung, skin, or auricular cartilage (58). The importance of LasA and LasB as virulence factors is demonstrated by a study reporting an about 70% reduction in *in vitro* invasion of epithelia cells for mutants deficient in one of the enzymes, whereas loss of both enzymes caused a further decrease in the invasive capacity of the cell (59). As indicated above, we observed an increase of about 5-fold in elastase levels *in vitro* at 0.2 mM Pi with respect to 1 mM Pi (Fig. 2A).

Two other exported proteins, the LapA and LapB phosphatases, were both not detected in the 1 mM Pi condition, whereas significant levels were detected under Pi




FIG 7 Changes in the abundance of ribosomal proteins of *P. aeruginosa* grown in the presence of 0.2 mM Pi compared to 1 mM. Red, decrease; gray, no significant difference. The numbers indicate the \log_2 fold change of iBAQ values. The fact that the fold change values are associated with genes does not imply that regulation is at the transcriptional level. The upper part shows the three-dimensional structures of the large and small ribosomal subunits of the PA ribosome (pdb: 6SPD).

scarceness (Data Set S1). In a study monitoring biofilm formation using an *ex vivo* chronic wound model, the *lapA* gene was the most upregulated (\log_2 FC = 11.32) compared to planktonic growth, indicating that this phosphatase plays a key role in wound infection, making it a potential drug target (60). LapA/LapB and PhoA, another phosphatase with increased abundance, are thought to be independently exported by the Hxc and Xcp type II secretion systems, respectively (61, 62). The secretion of LapA via the Hxc system is considered a complementary means to acquire Pi in case PhoA secretion by the Hcp system has become limited (61).

The phospholipases PlcB and PlcN are secreted by the Xcp type II secretion system and a hyperbiofilm phenotype was reported in mutants defective in *plcB* or *plcN* (63). Both proteins were not detected in 1 mM Pi but were present at significant amounts under Pi limitation. Another enriched protein, EddA, has alkaline phosphatase and phosphodiesterase activities and was found to be essential for the defense against extracellular traps that are produced by neutrophil immune cells as a mechanism to fight microbial pathogens (64).

In PA, there are three gene clusters that encode three homologous type VI secretion systems (H1- to H3-T6SS) (65). These systems are molecular nanomachines that inject effectors into target eukaryotic and prokaryotic cells and promote survival under harmful conditions, challenging survival of competitor organisms and helping PA to prevail in specific environments (66). Pi starvation had a differential impact on the levels of type VI secretion systems (Table 3, Fig. 8). Several proteins encoded in the H3 cluster were accumulated (Table 3), whereas the level of proteins encoded in cluster H2 remained unchanged. Pi starvation had a differential impact on proteins of the H1

TABLE 3 A selection of proteins with increased abundance comparing growth in minimal medium plus 0.2 mM Pi with minimal medium plus 1 mM Pi

Locus tag	Gene	Protein name/function	Log ₂ FC ^a
Proteins related to phosphate and phosphonate transport and regulation			
PA3279	<i>oprP</i>	Phosphate-specific outer membrane porin OprP precursor	6.36
PA3280	<i>oprO</i>	Pyrophosphate-specific outer membrane porin OprO precursor	6.45
PA3383	<i>phnD</i>	Binding protein component of ABC phosphonate transporter	3.23
PA3384	<i>phnC</i>	ATP-binding component of ABC phosphonate transporter	ON/OFF
PA5360	<i>phoB</i>	Two-component response regulator PhoB	6.33
PA5365	<i>phoU</i>	Phosphate uptake regulatory protein PhoU	3.56
PA5366	<i>pstB</i>	ATP-binding component of ABC phosphate transporter	3.44
PA5367	<i>pstA</i>	Membrane protein component of ABC phosphate transporter	3.73
PA5368	<i>pstC</i>	Membrane protein component of ABC phosphate transporter	2.68
PA5369	<i>pstS</i>	Phosphate ABC transporter, periplasmic phosphate-binding protein	2.66
Secretion systems			
Type II secretion systems			
PA0681	<i>hxcT</i>	Hxc type II secretion system	ON/OFF
PA0684	<i>hxcZ</i>	Hxc type II secretion system	ON/OFF
PA0685	<i>hxcQ</i>	Hxc type II secretion system	ON/OFF
PA0688	<i>lapA</i>	Alkaline phosphatase A (secreted by Hxc secretion system)	ON/OFF
PA0689	<i>lapB</i>	Alkaline phosphatase B (secreted by Hxc secretion system)	ON/OFF
PA0690	<i>pdtA</i>	Phosphate depletion regulated TPS partner A, type II secretion system	ON/OFF
PA3105	<i>xcpQ</i>	Xcp type II secretion system	2.67
PA3102	<i>xcpS</i>	Xcp type II secretion system	ON/OFF
PA0026	<i>plcB</i>	Phospholipase C (secreted by Xcp secretion system)	ON/OFF
PA0852	<i>cbpD</i>	Chitin-binding protein CbpD (secreted by Xcp secretion system)	4.46
PA3296	<i>phoA</i>	Alkaline phosphatase (secreted by Xcp secretion system)	3.03
PA3319	<i>plcN</i>	Nonhemolytic phospholipase C (secreted by Xcp secretion system)	ON/OFF
PA2939	<i>paAP</i>	Aminopeptidase (secreted by Xcp secretion system)	ON/OFF
PA0572	<i>pmpA</i>	Putative protease (secreted by Xcp secretion system)	5.10
PA1871	<i>lasA</i>	Elastase A (secreted by Xcp secretion system)	ON/OFF
PA0347	<i>glpQ</i>	Glycerophosphoryl diester phosphodiesterase (secreted by Xcp secretion system)	5.31
PA3910	<i>eddA</i>	Extracellular DNA degradation protein (secreted by Xcp secretion system)	ON/OFF
Type VI secretion systems			
PA0082	<i>tssA1</i>	Type VI secretion system H1	1.22
PA0083	<i>tssB1</i>	Type VI secretion system H1	0.85
PA0086	<i>tagJ1</i>	Type VI secretion system H1	0.82
PA2363	<i>hsiJ3</i>	Type VI secretion system H3	ON/OFF
PA2365	<i>hsiB3</i>	Type VI secretion system H3	ON/OFF
PA2366	<i>hsiC3</i>	Type VI secretion system H3	ON/OFF
PA3905	<i>tecT</i>	Type VI effector chaperone for Tox-Release	1.46
PA0263 ^b	<i>hcpC</i>	Type VI secretion system (protein of the spear)	2.35
PA5267 ^b	<i>hcpB</i>	Type VI secretion system (protein of the spear)	2.35
PA1512 ^b	<i>hcpA</i>	Type VI secretion system (protein of the spear)	2.35
PA1844	<i>tse1</i>	Type VI secretion system (secreted protein, peptidoglycan amidase)	1.30
Other enzymes involved in Pi metabolism (phosphatases, phospholipases, and diesterases)			
PA3885	<i>tpbA</i>	Protein tyrosine phosphatase	4.02
PA5292	<i>pchP</i>	Phosphorylcholine phosphatase	1.82
PA0843	<i>plcR</i>	Phospholipase accessory protein PlcR precursor	ON/OFF
PA2856	<i>tesA</i>	Lysophospholipase A	1.1
PA2990		Probable phosphodiesterase	0.95
Pyocyanin synthesis and activity			
PA4209	<i>phzM</i>	Phenazine-specific methyltransferase	2.99
PA4210	<i>phzA₁</i>	Phenazine biosynthesis protein	ON/OFF
PA4211	<i>phzB₁</i>	Phenazine biosynthesis protein	6.13
PA1900	<i>phzB₂</i>	Phenazine synthesis protein	4.16

(Continued on next page)

TABLE 3 (Continued)

Locus tag	Gene	Protein name/function	Log ₂ FC ^a
PA4213 ^b	<i>phzD₁</i>	Phenazine biosynthesis proteins	ON/OFF
PA1902 ^b	<i>phzD₂</i>	Phenazine biosynthesis proteins	ON/OFF
PA4214 ^b	<i>phzE₁</i>	Phenazine biosynthesis proteins	7.9
PA1903 ^b	<i>phzE₂</i>	Phenazine biosynthesis proteins	7.9
PA4215 ^b	<i>phzF₁</i>	Phenazine biosynthesis proteins	4.46
PA1904 ^b	<i>phzF₂</i>	Phenazine biosynthesis proteins	4.46
PA4216 ^b	<i>phzG₁</i>	Pyridoxamine 5'-phosphate oxidase	7.33
PA1905 ^b	<i>phzG₂</i>	Pyridoxamine 59-phosphate oxidase	7.33
PA4217	<i>phzS</i>	Flavin-containing monoxygenase	2.92
Che ₂ chemosensory pathway			
PA0176	<i>aer₂</i>	Chemoreceptor Aer ₂ /McpB	1.62
PA0177	<i>cheW₂</i>	Coupling protein	3.33
PA0179	<i>cheY₂</i>	Response regulator	2.53
Quorum sensing			
PA0997	<i>pqsB</i>	HHQ/PQS synthesis	3.74
PA0998	<i>pqsC</i>	HHQ/PQS synthesis	2.59
PA0999	<i>pqsD</i>	3-oxoacyl-[acyl-carrier-protein] synthase III	4.43
PA1001	<i>phnA</i>	Anthranilate synthase component I	ON/OFF
PA1002	<i>phnB</i>	Anthranilate synthase component II	ON/OFF
PA2303	<i>ambD</i>	Synthesis of the IQS signal	3.63
PA2304	<i>ambC</i>	Synthesis of the IQS signal	3.37
PA3476	<i>rhII</i>	C4-HSL autoinducer synthesis protein	2.22
PA3477	<i>rhIR</i>	Transcriptional regulator RhIR	3.88
Signal transduction			
PA0675	<i>vrel</i>	ECF sigma factor	ON/OFF
PA0676	<i>vreR</i>	Sigma factor regulator	ON/OFF
PA0696		Unknown function, part of the σ^{Vrel} regulon	5.92
PA0698		Unknown function, part of the σ^{Vrel} regulon	5.80
PA2047	<i>cmrA</i>	Transcriptional regulator of multidrug efflux pump	1.66
PA2895	<i>sbrR</i>	Anti-sigma factor, inhibits SbrI	1.43
PA2899	<i>atvR</i>	Atypical virulence-related response regulator AtvR	1.52
PA3161	<i>himD</i>	Integration host factor beta subunit	1.67
PA3347	<i>hsbA</i>	HptB-dependent secretion and biofilm anti-sigma factor	1.41
PA3385	<i>amrZ</i>	Alginate and motility regulator Z	1.81
PA3622	<i>rpoS</i>	Sigma factor RpoS	2.33
PA3678	<i>mexL</i>	Transcriptional repressor of the <i>mexJK</i> multidrug efflux operon	0.81
PA4101	<i>bfmR</i>	Response regulator involved in biofilm formation	2.17
PA4381	<i>colR</i>	Response regulator involved in polymyxin resistance	1.36
PA4608	<i>mapZ</i>	C-di-GMP-binding adaptor protein, interacts with a chemotaxis methyltransferase to control flagellar motor switching	1.52
PA4778	<i>cueR</i>	Transcriptional regulator activated by LasR	0.81
PA4878	<i>brlR</i>	Pyocyanin binding transcriptional regulator that activates multidrug efflux pump	3.14
PA5261	<i>algR</i>	Alginate biosynthesis regulator	1.12
PA5360	<i>phoB</i>	Two-component response regulator PhoB	6.33
Other virulence related genes			
PA0122	<i>rahU</i>	Rhamnolipid-interacting protein that modulates innate immunity and inflammation in host cells. Involved in biofilm formation	0.91
PA0355	<i>pfpi</i>	Protease involved in antibiotic resistance, swarming and biofilm formation	4.05
PA1249	<i>aprA</i>	Alkaline protease, degrades transferrin, complement proteins, cytokines, and components of the extracellular matrix	ON/OFF
PA3479	<i>rhIA</i>	Rhamnosyltransferase chain A	ON/OFF
PA3550	<i>algF</i>	Alginate o-acetyltransferase	2.53
PA3552	<i>arnB</i>	Uridine 5'-(beta-1-threo-pentapyranosyl-4-ulose diphosphate) aminotransferase with critical role in colistin resistance	ON/OFF
PA3692	<i>lptF</i>	Lipotoxin F, outer membrane protein, necessary for adhesion to human cells	1.34

(Continued on next page)

TABLE 3 (Continued)

Locus tag	Gene	Protein name/function	Log ₂ FC ^a
PA4379	<i>warA</i>	Methyltransferase involved in LPS biosynthesis	ON/OFF
PA4667	<i>lbcA</i>	Lipoprotein binding partner of CtpA, required for type III secretion system function and virulence	0.91

^aON/OFF corresponds to proteins that were detected in the three replicates of samples derived from growth in 0.2 mM Pi, but that were not detected any of the three replicates of samples derived from growth at 1 mM Pi.

^bProteins of the same sequence.

cluster for which abundances were either increased or decreased (Table 3, Fig. 8; Data Set S2). One of the toxins secreted by the H1 system, Tse1, is among the accumulated proteins under Pi limitation.

(iii) Other enzymes involved in Pi metabolism. Next to the enriched phosphatases and phospholipases that are substrates for secretion systems, several other enzymes involved in Pi metabolism showed increased levels in Pi-limited conditions (Table 3). Among them is the tyrosine phosphatase TpbA that plays a key role in PA physiology. TpbA specifically controls the phosphorylation state of the transmembrane diguanylate cyclase TpbB (PA1120) by dephosphorylating Tyr and Ser/Thr residues. This control of the phosphorylation state regulates TpbB activity which in turn determines central features in PA physiology like the rugose colony morphology, biofilm production, and swarming motility (67, 68). Pi starvation also increased levels of the phosphorylcholine phosphatase PchP. Among the mechanisms required for the colonization of different tissues is the breakdown of host membrane phospholipids, a reaction catalyzed by PchP resulting in choline and Pi (69). A mutant in *plcR* was 200-fold less virulent in a mouse infection model (70). PlcR is an accessory protein that was found to be essential for the secretion of the PlcH phospholipase. In our study, PlcR was enriched (Table 3) whereas PlcH was depleted (\log_2 FC = 3; Data Set S2) (71). It may be possible that PlcR is also required for the secretion of other phospholipases.

(iv) Pyocyanin synthesis and activity. Chorismate is the end product of the shikimate pathway that was downregulated under Pi-limiting conditions (Fig. 5). However, the routes that convert chorismate into the QS signal 4-hydroxy-2-heptylquinoline (HHQ) and the phenazines pyocyanin, phenazine, and 1-hydroxyphenazine were strongly upregulated (Fig. 9). Several proteins involved in phenazine biosynthesis were among those with the largest increase, as detailed in Table 2, and pyocyanin production was dramatically enhanced under Pi starvation (Fig. 1B–D). Pyocyanin is a redox-active compound that is secreted into the medium. It is one of PA's primary virulence factors and is required to establish infection (72). Due to its redox activity, pyocyanin toxicity has been associated with the inhibition of aerobic respiration and the production of reactive oxygen species (73), and promoting virulence by interfering with numerous cellular functions in host cells (74). The different phenazines are considered biomarkers of PA infections (72).

(v) Che₂ chemosensory pathway. PA has four chemosensory pathways. Of these, the Che pathway mediates chemotaxis and the Wsp pathway controls c-di-GMP levels, whereas the Chp pathway is associated with mechanosensing and type IV pili-based motility (75). Although the function of the fourth pathway, Che₂, is unknown, there are multiple pieces of evidence indicating that it plays an important role in virulence. It has been shown that the deletion of the genes encoding the sole chemoreceptor that stimulates this pathway, Aer₂/McpB, as well as the CheB₂ methyltransferase caused a reduction in virulence (76, 77). Under Pi scarcity, three proteins of the Che₂ pathway were accumulated, namely, the McpB chemoreceptor, the CheW₂ adaptor protein, and the CheA₂ autokinase (Fig. 10). In accordance with our results, different genes of the Che₂ pathway were upregulated in a transcriptomic study at low Pi levels (18).

(vi) Quorum sensing. So far four QS systems have been reported in PA, namely, the Las, Rhl, Pqs, and Iqs systems. The Las and Rhl systems involve the synthesis and detection of the acylhomoserine lactone QS signals *N*-3-oxododecanoylhomoserine lactone (3-oxo-C12-HSL) and *N*-butanoylhomoserine lactone (C4-HSL), respectively (Fig. 11).




FIG 9 Changes in the abundance of proteins involved in the synthesis of quorum sensing signals and phenazines of *P. aeruginosa* grown in the presence of 0.2 mM Pi compared to 1 mM. Blue, increase; gray, no significant difference; NaN, not a number (not detected in the three replicates of the 1 mM Pi sample but identified in the three replicates of the 0.2 mM Pi sample). The numbers indicate the log₂ fold changes of iBAQ values. Values separated by a slash are those of the individual subunits of an enzyme.

pyocyanin synthesis, the LasA protease, the PlcB phospholipase, Che₂ pathway proteins, components of type II and type VI secretion system, or other proteins involved in virulence like the PfpI protease, lipotoxin F (LptF) or the RhlR/RhlI pair and those of several proteins that are required for the synthesis of quinolone and IQS QS signals (Fig. 11). In contrast, an important depletion of the LasI synthase was noted, suggesting that the accumulation of the Rhl, Pqs, and Iqs proteins is not primarily mediated by the Las system under Pi-limited conditions, in accordance with transcriptomics studies (24, 80).

(vii) Signal transduction proteins. Pi scarceness also altered the levels of a significant number of signal transduction proteins of which the most relevant examples are listed in Table 3. Next to the very significant increase observed for proteins of the VreIR ECF system and the PhoB response regulator, notable increases were also observed for other response regulators, ColR, AtvR, and BfmR, as well as the transcription factors CmrA, MexL, and AmrZ. ColR is involved in conferring polymyxin resistance (81) and AtvR was associated with PA adaptation to anaerobic conditions during infection (82). BfmR was shown to be essential for biofilm maturation (83) and its activation caused a shift from acute to chronic infection (84). MexL, BrlR, and CmrA regulate the expression of multidrug efflux pumps (85, 86). Interestingly, pyocyanin was shown to bind to BrlR, in turn enhancing BrlR-DNA affinity (87). AmrZ regulates twitching motility and alginate biosynthesis, two processes required for biofilm development (88, 89). Furthermore, this regulator orchestrates the assembly of all three type VI secretion systems (90). Further proteins with increased levels include the RpoS sigma factor that plays a central role in QS-mediated regulation (91), and MapZ, that controls the methylation state of chemoreceptors and consequently chemotaxis (92), another important virulence trait (78).

(viii) Other proteins involved in virulence. Several additional proteins with diverse roles in virulence were among the accumulated proteins (Table 3). An example is the rhamnolipid-interacting protein RhlU, that is under the control of the Rhl QS system (93). RhlU is involved in biofilm formation (94) and was shown to interfere with host innate immunity by inhibiting the accumulation of nitric oxide and chemotaxis of different immune cells (95). The protease PfpI was upregulated more than 16-fold (Table 3) and mutants defective in *pfpI* showed an increased resistance to ciprofloxacin, reduced swarming motility, and biofilm formation (96). Higher protein amounts were also observed for the RhlA rhamnolipid transferase and the ArnB aminotransferase, two enzymes essential for the synthesis of rhamnolipids (97) and involved in the production of an arabinose derivative that forms part of lipopolysaccharides (LPSs) (98),




FIG 10 Changes in the abundance of signaling proteins of the Che₂ pathway of *P. aeruginosa* grown in the presence of 0.2 mM Pi compared to 1 mM. Blue, increase; gray, no significant difference or not detected; the numbers indicate the log₂ fold changes of iBAQ values. H1 to H5: HAMP (found in histidine kinases, adenylate cyclases, methyl accepting proteins) domains.

respectively. Colistin is a last-resort antibiotic to fight PA and colistin resistant mutants showed increased amounts of ArnB (99). Furthermore, the WarA methyltransferase interacts with the LPS biogenesis machinery and contributes to the ability of PA to evade detection by the host (100), most likely due to the role of LPSs as host immune response modulator. LbcA is a lipoprotein that forms a complex with the CtpA protease. LbcA is essential for the proteolytic activity of CtpA that in turn is required for the function of a type III secretion system and virulence in a mouse model of acute pneumonia (101, 102). Lastly, it is worth mentioning that the outer membrane protein, LptF, which has been associated with antibiotic resistance (103), was also enriched (Table 3).

Conclusions and future perspectives. An increase in bacterial virulence caused by Pi limitation appears to be a general regulatory mechanism since it has been observed for several bacterial pathogens that differ in phylogeny, lifestyle, and virulence mechanisms (11–17). Phosphate therapy, or the reduction of bacterial virulence by the administration of Pi (or phosphate-containing compounds), is a promising approach to fight microbial pathogens that will not cause cytotoxicity nor the development of antibiotic resistance. The proof of concept for phosphate therapy has been obtained using primarily PA as a model organism (21, 29, 31, 32, 35, 36). In this study, we have determined the changes in the PA proteome caused by alterations in the Pi concentration.

Using the synthesis of pyocyanin as a proxy for the regulatory action of Pi, we show that changes occur in a very small window of Pi concentrations. Whereas almost no pyocyanin is synthesized in the presence of 0.6 mM Pi, a 3-fold decrease in the Pi concentration caused about a 75-fold increase in the pyocyanin levels, indicative of a highly cooperative process. Our proteomics analyses identified at least part of the molecular basis for the cooperativity




FIG 11 Changes in the abundance of proteins involved in quorum sensing of *P. aeruginosa* grown in the presence of 0.2 mM Pi compared to 1 mM. Blue, increase; red, decrease; gray, no significant difference or not detected; the numbers indicate the \log_2 fold changes of iBAQ values. NaN, not a number (not detected in the three replicates of the 1 mM Pi sample but identified in the three replicates of the 0.2 mM Pi sample). HSL, homoserine lactone; HHQ, 4-hydroxy-2-heptylquinoline; PQS, 2-heptyl-3-hydroxy-4-quinolone.

observed. Pi is sensed by the PstABCS/PhoRBU complex (50), and Pi scarceness caused large increases in the protein levels of this sensory complex (Table 2 and 3) resulting in a feed-forward regulatory circuit and positive cooperativity.

As mentioned above, Pi scarceness increases the virulence of many different pathogens by an overexpression of different virulence factors. However, our study shows that of the 1,471 dysregulated proteins, the large majority, 1,100, were detected with lower abundance. Most of the depleted proteins are involved in general and energy metabolism, transport, and many different biosynthetic and catabolic routes (Fig. 5) or form part of the ribosome (Fig. 7). This issue is also illustrated by comparing the transcriptomics study of Bains et al. (18) with our proteomics data. In both studies, PAO1 was cultured under the same growth conditions and exposed to either 0.2 mM or 1 mM Pi. Fig. 12 is a Venn diagram of the up- and downregulated genes/proteins in both studies. Whereas a balance in the number of upregulated genes/proteins is observed between both studies, there is a large excess of downregulated proteins compared to the genes that were downregulated in the transcriptomics study (Fig. 12) (18). These data suggest the existence of strong posttranscriptional regulatory mechanisms that are responsible for the vast majority of depleted proteins.

Many of the accumulated proteins in our study are known to be regulated by quorum sensing, suggesting that QS is a key mechanism by which Pi induces the corresponding changes. In general, the four QS systems in PA are arranged in a hierarchical order with the Las system on top, controlling the activity of the Rhl, Pqs, and Iqs systems (78). However, this general scheme does not appear to apply to QS-mediated




FIG 12 Venn diagram comparing genes/proteins regulated by an exposure of PA PAO1 to 0.2 mM and 1 mM Pi in a transcriptomics study (18) and our proteomics analysis. The culture conditions in both studies were identical. Since in the transcriptomics study, a cutoff 2-fold change was applied, the dysregulated proteins in the proteomics study were truncated at the same level.

changes under Pi-scarce conditions. Indeed, a recent study (25) has shown that: (i) the Las system is globally dispensable for mediating responses to low Pi; (ii) LasR expression is not affected by phosphate limitation; (iii) PhoB directly regulates *rhIR* transcription; and (iv) mutation of *pqsR* reduced pyocyanin production as a whole, suggesting that under phosphate limitation, the Rhl system is on top of the QS regulatory hierarchy. However, contrary to these findings, an alternative study revealed that PhoB activated *lasI* expression, the gene encoding the homoserine lactone (HSL) synthesizing enzyme of the Las system, under phosphate depletion conditions (26). Our proteomics data largely support the notion that QS-mediated regulation in response to Pi limitation is Las independent and governed by the Rhl system. Pi scarcity significantly reduced LasI levels, did not alter LasR levels, but increased components of the Rhl (e.g., RhlI, RhlR, RhlA), Pqs (e.g., PhnA, PhnB, PqsB, PqsC, PqsD) and Iqs (e.g., AmbC, AmbD) systems (Fig. 9 and 11).

A recent review has classified the different virulence hallmarks of PA according to their function into the following 6 groups: factors for host colonization and bacterial motility, biofilm formation, production of destructive enzymes, toxic secondary metabolites, iron-chelating siderophores, and toxins (47). Representatives of all six categories were among the proteins that were upregulated by Pi limitation. Abundances of several key virulence factors identified for each of these six categories were increased in our study, including PstS, LasA, AprA, PlcB, PlcN, PhzABDEFG, RhlAIR, PqsBCD, and AlgFR (47). Pi limitation has been observed following surgical injury, leading to an increased bacterial virulence (20, 21). This enhanced virulence is due to an induction of proteins that belong to all six major categories of virulence hallmarks. However, the administration of Pi to patients to increase its concentration above 0.5 mM will result in a reversal of virulence protein induction. Phosphate therapy thus holds a strong promise as an alternative strategy to tackle microbial pathogens.

MATERIALS AND METHODS

Bacterial strains and growth conditions. PA PAO1 was grown at 37°C with orbital shaking (200 rpm) in LB (5 g/L yeast extract, 10 g/L bactotryptone, 5 g/L NaCl) or MM (0.1 M HEPES, 7 mM $[\text{NH}_4]_2\text{SO}_4$, 20 mM succinate, 1 mM MgSO_4 , 6 mg/L Fe-citrate, 300 mg/L HBO_3 , 50 mg/L ZnCl_2 , 30 mg/L $\text{MnCl}_2 \times 4 \text{H}_2\text{O}$, 200 mg/L CoCl_2 , 10 mg/L $\text{CuCl}_2 \times 2 \text{H}_2\text{O}$, 20 mg/L $\text{NiCl}_2 \times 6 \text{H}_2\text{O}$, 30 mg/L $\text{NaMoO}_4 \times 2 \text{H}_2\text{O}$, pH 7.0) containing 0.1 to 50 mM potassium phosphate ($\text{K}_2\text{HPO}_4/\text{KH}_2\text{PO}_4$, pH 7.0).

Quantification of the supernatant Pi concentration during bacterial growth. Determination of Pi concentration along the growth curve was carried out using the malachite green phosphate assay kit (Sigma-Aldrich; Catalog number MAK307) following the manufacturer's instructions. Reaction assays

were incubated for 30 min at room temperature for color development, followed by an absorbance measurement at 660 nm using a Sunrise plate reader from Tecan (Männedorf, Switzerland).

Phenotypic assays. Assays for pyocyanin quantification, antibacterial activity, and extracellular enzyme production (e.g., proteases and elastase) were carried out on culture supernatants from PA PAO1 cells grown in MM with different Pi concentrations. Overnight cultures of PAO1 grown in MM containing 1 mM inorganic phosphate (K_2HPO_4/KH_2PO_4) were washed twice with phosphate-free MM and then used to inoculate flasks containing 15 mL MM with 0.1 to 1 mM Pi at an initial OD_{660} of 0.075 and grown for 24 h at 37°C with orbital shaking (200 rpm). After overnight growth, bacterial cultures were centrifuged at $9,000 \times g$ for 10 min and the supernatants were filtered (0.2 μm cutoff). The resulting filter-sterilized supernatants were used to conduct the following bioassays.

(i) Pyocyanin quantification. Pyocyanin was extracted into chloroform by mixing 7.5 mL of each of the supernatants with 4.5 mL of chloroform. Pyocyanin was further extracted from the solvent phase into 1.5 mL of 0.2 M HCl. The absorbance of the resulting solution was measured at 520 nm and data normalized against cell density at 660 nm.

(ii) Antibacterial assays. Antibiotic activity was tested by the agar lawn assay using 0.8% LB agar plates containing a top lawn of 200 μL of an overnight culture of *Chromobacterium violaceum* CV026 (104). Next, 300 μL of filter-sterilized PAO1 supernatants were added to wells punched into the plates and incubated at 30°C for 48 h.

(iii) Elastase activity determination. One milliliter supernatant was added to tubes containing 10 mg elastin-Congo red (ECR; Merck) and 1 mL of 0.1 M Tris/HCl, 1 mM $CaCl_2$ (pH 7.0). Tubes were incubated at 37°C with shaking (200 rpm) for 24 h and the reactions stopped by the addition of 1 mL 0.7 M sodium phosphate buffer pH 6.0. Residual, solid ECR was removed by centrifugation and the OD_{492} of the reaction was measured. These measurements were normalized against the absorbance at OD_{492} of the cell-free supernatants prior to the addition of ECR and against cell density at 660 nm.

Protease activity. Qualitative proteolysis assays were conducted using the skim milk assay. Briefly, 300 μL supernatants were added to wells punched into the skim milk plates (1% skim milk – quarter-strength LB) and incubated at 30°C for 48 h. Skim milk proteolysis was evaluated as the zone of clearance from the well edge.

Sample preparation for mass spectrometry (MS). Overnight cultures of PA PAO1 grown in MM containing 1 mM Pi (K_2HPO_4/KH_2PO_4 , pH 7.0) were washed twice with Pi-free MM. Washed cultures were then used to inoculate flasks with 50 mL MM containing high (1 mM) and low (0.2 mM) Pi concentrations at an OD_{660} of 0.075 and grown at 37°C with orbital shaking (200 rpm). At an OD_{660} of 0.6, 40 mL aliquots were centrifuged at $9,000 \times g$ for 10 min. The resulting pellets were resuspended in 2 mL extraction buffer (6 M urea, 2 M thiourea, 50 mM Tris/CL, pH 7.5) and cells were broken by sonication. After centrifugation at $9,200 \times g$ for 10 min, supernatants were collected, and protein concentration was determined by the Bradford assay (Bio-Rad, reference no. 500-0006). Supernatant aliquots were subsequently mixed with 5 \times Laemmli sample buffer containing 1 mM β -mercaptoethanol. After 1 h of incubation at room temperature, aliquots corresponding to 25 μg of protein were run on a 4 to 20% precast polyacrylamide gel (Bio-Rad, reference no. 4561094) at 95 V. The polyacrylamide gel was fixed with solution A (40% [vol/vol] methanol, 7% [vol/vol] acetic acid) for 10 min and stained with solution B (0.1% [wt/vol] Coomassie brilliant blue R [Sigma-Aldrich, Ref. B7920], 40% [vol/vol] methanol, 10% [vol/vol] acetic acid). The gel was finally destained with solution A. Proteins were prepared for tandem mass spectrometry analyses, as previously described (105). Briefly, gel lanes were fractionated into 10 gel pieces, cut into smaller blocks, and transferred into low binding tubes. Samples were washed until gel blocks were destained and dried in a vacuum centrifuge before they were covered with a trypsin solution. Samples were digested overnight at 37°C prior to peptide elution into water by ultrasonication treatment. The peptide-containing supernatants were transferred into fresh tubes, desiccated in a vacuum centrifuge and peptides were resolubilized in 0.1% (vol/vol) acetic acid for mass spectrometric analysis.

MS/MS analysis. LC-MS/MS analyses were performed on a LTQ Orbitrap VelosPro instrument (ThermoFisher Scientific, Waltham, MA, USA) using an EASY-nLC II liquid chromatography system. Tryptic peptides were subjected to liquid chromatography separation and electrospray ionization-based MS applying the same injected volumes in order to allow for label-free relative protein quantification between and within samples. Therefore, peptides were loaded on a self-packed analytical column (OD 360 μm , ID 100 μm , length 20 cm) filled with 3- μm diameter C18 particles (Maisch, Ammerbuch-Entringen, Germany) and eluted by a binary nonlinear gradient of 5 to 99% acetonitrile in 0.1% (vol/vol) acetic acid over 87 min with a flow rate of 300 nL/min. For MS analysis, a full scan in the Orbitrap with a resolution of 30,000 was followed by collision-induced dissociation (CID) of the 20 most abundant precursor ions. MS/MS experiments were acquired in the linear ion trap.

MS data analysis. Database searches against a database of PA PAO1 downloaded from the *Pseudomonas* Genome DB (48) on 6 October 2021 (5,587 entries) as well as Intensity-Based Absolute Quantification (iBAQ) were performed using MaxQuant (version 1.6.17.0) (106). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies, and proteome-wide protein quantification (107). Common laboratory contaminants and reversed sequences were included by MaxQuant. Search parameters were set as follows: trypsin/P-specific digestion with up to two missed cleavages, methionine oxidation and N-terminal acetylation as variable modification, match between runs with default parameters enabled. The false discovery rates (FDRs) of protein and peptide spectrum match (PSM) levels were set to 0.01. Two identified unique peptides were required for protein identification. Results were filtered for proteins quantified in at least two out of three biological replicates before statistical analysis. Here, protein from PAO1 grown in MM supplemented with 0.2 mM and 1 mM Pi were compared by a Student's *t* test applying a threshold *P* value of 0.01, which was based on all possible

permutations. Proteins were considered differentially abundant if the log₂ fold change was greater than 0.8. “ON/OFF proteins” were defined as being identified in all bioreplicates of one condition, whereas the protein was not identified in any replicate of the other condition.

Bioinformatics. Heatmap and hierarchical clustering analyses of the detected and differentially expressed proteins were made using the ComplexHeatmap version 2.9.3 package in R (108). Biological pathway enrichment analysis of differentially expressed proteins was performed using the BlastKOALA tool from the Kyoto Encyclopedia of Genes and Genomes (KEGG) (109). Fig. 4 to 10 were created using BioRender.com.

Data availability. The MS data reported in this publication have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository (110) with data set identifier [PXD033250](https://doi.org/10.26434/chemrxiv-2022-pxd03).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, XLSX file, 0.7 MB.

SUPPLEMENTAL FILE 2, XLSX file, 0.3 MB.

SUPPLEMENTAL FILE 3, XLSX file, 0.1 MB.

ACKNOWLEDGMENTS

This work was supported by grants PID2019-103972GA-I00 (to M.A.M.) and PID2020-112612GB-I00 (to T.K.) from the Spanish Ministry for Science and Innovation/Agencia Estatal de Investigación 10.13039/501100011033 and grant P18-FR-1621 (to T.K.) from the Junta de Andalucía.

The authors do not declare a conflict of interest.

REFERENCES

- Crone S, Vives-Flórez M, Kvich L, Saunders AM, Malone M, Nicolaisen MH, Martínez-García E, Rojas-Acosta C, Catalina Gomez-Puerto M, Calum H, Whiteley M, Kolter R, Bjarnsholt T. 2020. The environmental occurrence of *Pseudomonas aeruginosa*. *APMIS* 128:220–231. <https://doi.org/10.1111/apm.13010>.
- Bel Hadj Ahmed A, Salah Abbassi M, Rojo-Bezares B, Ruiz-Roldán L, Dhahri R, Mehri I, Sáenz Y, Hassen A. 2020. Characterization of *Pseudomonas aeruginosa* isolated from various environmental niches: new STs and occurrence of antibiotic susceptible “high-risk clones. *Int J Environ Health Res* 30:643–652. <https://doi.org/10.1080/09603123.2019.1616080>.
- Bédard E, Prévost M, Déziel E. 2016. *Pseudomonas aeruginosa* in premise plumbing of large buildings. *Microbiologyopen* 5:937–956. <https://doi.org/10.1002/mbo3.391>.
- Iglewski BH. 1996. Chapter 27 *Pseudomonas*. In Baron S (ed), *Medical Microbiology*, 4th edition. University of Texas Medical Branch, Galveston, Galveston (TX).
- Morata L, Cobos-Trigueros N, Martínez JA, Soriano A, Almela M, Marco F, Sterzik H, Núñez R, Hernández C, Mensa J. 2012. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of *Pseudomonas aeruginosa* bacteremia. *Antimicrob Agents Chemother* 56:4833–4837. <https://doi.org/10.1128/AAC.00750-12>.
- Sindeldecker D, Stoodley P. 2021. The many antibiotic resistance and tolerance strategies of *Pseudomonas aeruginosa*. *Biofilm* 3:100056. <https://doi.org/10.1016/j.biofilm.2021.100056>.
- Jean SS, Chang YC, Lin WC, Lee WS, Hsueh PR, Hsu CW. 2020. Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia. *JCM* 9:275. <https://doi.org/10.3390/jcm9010275>.
- Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. 2003. *Pseudomonas aeruginosa* bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. *Clin Infect Dis* 37:745–751. <https://doi.org/10.1086/377200>.
- Walker TS, Bais HP, Deziel E, Schweizer HP, Rahme LG, Fall R, Vivanco JM. 2004. *Pseudomonas aeruginosa*-plant root interactions. Pathogenicity, biofilm formation, and root exudation. *Plant Physiol* 134:320–331. <https://doi.org/10.1104/pp.103.027888>.
- Rahme LG, Ausubel FM, Cao H, Drenkard E, Goumnerov BC, Lau GW, Mahajan-Miklos S, Plotnikova J, Tan MW, Tsongalis J, Walendziewicz CL, Tompkins RG. 2000. Plants and animals share functionally common bacterial virulence factors. *Proc Natl Acad Sci U S A* 97:8815–8821. <https://doi.org/10.1073/pnas.97.16.8815>.
- von Kruger WM, Lery LM, Soares MR, de Neves-Manta FS, Batista e Silva CM, Neves-Ferreira AG, Perales J, Bisch PM. 2006. The phosphate-starvation response in *Vibrio cholerae* O1 and *phoB* mutant under proteomic analysis: disclosing functions involved in adaptation, survival and virulence. *Proteomics* 6:1495–1511. <https://doi.org/10.1002/pmic.200500238>.
- Aggarwal S, Somani VK, Bhatnagar R. 2015. Phosphate starvation enhances the pathogenesis of *Bacillus anthracis*. *Int J Med Microbiol* 305:523–531. <https://doi.org/10.1016/j.ijmm.2015.06.001>.
- Elliott SR, White DW, Tischler AD. 2019. *Mycobacterium tuberculosis* requires regulation of ESX-5 secretion for virulence in *Irgm1*-deficient mice. *Infect Immun* 87:e00660-18. <https://doi.org/10.1128/IAI.00660-18>.
- Kelliher JL, Radin JN, Kehl-Fie TE. 2018. PhoPR contributes to *Staphylococcus aureus* growth during phosphate starvation and pathogenesis in an environment-specific manner. *Infect Immun* 86:e00371-18. <https://doi.org/10.1128/IAI.00371-18>.
- Aoyama T, Takanami M, Makino K, Oka A. 1991. Cross-talk between the virulence and phosphate regulons of *Agrobacterium tumefaciens* caused by an unusual interaction of the transcriptional activator with a regulatory DNA element. *Mol Gen Genet* 227:385–390. <https://doi.org/10.1007/BF00273927>.
- Zheng D, Xue B, Shao Y, Yu H, Yao X, Ruan L. 2018. Activation of PhoBR under phosphate-rich conditions reduces the virulence of *Xanthomonas oryzae* pv. *oryzae*. *Mol Plant Pathol* 19:2066–2076. <https://doi.org/10.1111/mpp.12680>.
- Köhler JR, Acosta-Zaldívar M, Qi W. 2020. Phosphate in virulence of *Candida albicans* and *Candida glabrata*. *JoF* 6:40. <https://doi.org/10.3390/jof6020040>.
- Bains M, Fernandez L, Hancock RE. 2012. Phosphate starvation promotes swarming motility and cytotoxicity of *Pseudomonas aeruginosa*. *Appl Environ Microbiol* 78:6762–6768. <https://doi.org/10.1128/AEM.01015-12>.
- Zaborin A, Romanowski K, Gerdes S, Holbrook C, Lepine F, Long J, Poroyko V, Diggle SP, Wilke A, Righetti K, Morozova I, Babrowski T, Liu DC, Zaborina O, Alverdy JC. 2009. Red death in *Caenorhabditis elegans* caused by *Pseudomonas aeruginosa* PAO1. *Proc Natl Acad Sci U S A* 106:6327–6332. <https://doi.org/10.1073/pnas.0813199106>.
- Shor R, Halabe A, Rishver S, Tilis Y, Matas Z, Fux A, Boaz M, Weinstein J. 2006. Severe hypophosphatemia in sepsis as a mortality predictor. *Ann Clin Lab Sci* 36:67–72.
- Long J, Zaborina O, Holbrook C, Zaborin A, Alverdy J. 2008. Depletion of intestinal phosphate after operative injury activates the virulence of *P aeruginosa* causing lethal gut-derived sepsis. *Surgery* 144:189–197. <https://doi.org/10.1016/j.surg.2008.03.045>.

22. Salem RR, Tray K. 2005. Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia. *Ann Surg* 241:343–348. <https://doi.org/10.1097/01.sla.0000152093.43468.c0>.
23. Lamarche MG, Wanner BL, Crepin S, Harel J. 2008. The phosphate regulation and bacterial virulence: a regulatory network connecting phosphate homeostasis and pathogenesis. *FEMS Microbiol Rev* 32:461–473. <https://doi.org/10.1111/j.1574-6976.2008.00101.x>.
24. Lee J, Wu J, Deng Y, Wang J, Wang C, Wang J, Chang C, Dong Y, Williams P, Zhang LH. 2013. A cell-cell communication signal integrates quorum sensing and stress response. *Nat Chem Biol* 9:339–343. <https://doi.org/10.1038/nchembio.1225>.
25. Soto-Aceves MP, Cocotl-Yañez M, Servín-González L, Soberón-Chávez G. 2021. The Rhl Quorum-Sensing System Is at the Top of the Regulatory Hierarchy under Phosphate-Limiting Conditions in *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 203:e00475-20. <https://doi.org/10.1128/JB.00475-20>.
26. Meng X, Ahator SD, Zhang LH. 2020. Molecular mechanisms of phosphate stress activation of *Pseudomonas aeruginosa* quorum sensing systems. *mSphere* 5:e00119-20. <https://doi.org/10.1128/mSphere.00119-20>.
27. Thuong M, Arvaniti K, Ruimy R, de la Salmoniere P, Scanvic-Hameg A, Lucet JC, Regnier B. 2003. Epidemiology of *Pseudomonas aeruginosa* and risk factors for carriage acquisition in an intensive care unit. *J Hosp Infect* 53:274–282. <https://doi.org/10.1053/jhin.2002.1370>.
28. Muroño K, Hirano Y, Koyano S, Ito K, Fujieda K. 2003. Molecular comparison of bacterial isolates from blood with strains colonizing pharynx and intestine in immunocompromised patients with sepsis. *J Med Microbiol* 52:527–530. <https://doi.org/10.1099/jmm.0.05076-0>.
29. Romanowski K, Zaborin A, Fernandez H, Poroyko V, Valuckaite V, Gerdes S, Liu DC, Zaborina OY, Alverdy JC. 2011. Prevention of siderophore-mediated gut-derived sepsis due to *P aeruginosa* can be achieved without iron provision by maintaining local phosphate abundance: role of pH. *BMC Microbiol* 11:212–212. <https://doi.org/10.1186/1471-2180-11-212>.
30. Romanowski K, Zaborin A, Valuckaite V, Rolfes RJ, Babrowski T, Bethel C, Olivas A, Zaborina O, Alverdy JC. 2012. *Candida albicans* isolates from the gut of critically ill patients respond to phosphate limitation by expressing filaments and a lethal phenotype. *PLoS One* 7:e30119. <https://doi.org/10.1371/journal.pone.0030119>.
31. Zaborin A, Defazio JR, Kade M, Kaiser BL, Belogortseva N, Camp DG, 2nd, Smith RD, Adkins JN, Kim SM, Alverdy A, Goldfeld D, Firestone MA, Collier JH, Jabri B, Tirrell M, Zaborina O, Alverdy JC. 2014. Phosphate-containing polyethylene glycol polymers prevent lethal sepsis by multidrug-resistant pathogens. *Antimicrob Agents Chemother* 58:966–977. <https://doi.org/10.1128/AAC.02183-13>.
32. Mao J, Zaborin A, Poroyko V, Goldfeld D, Lynd NA, Chen W, Tirrell MV, Zaborina O, Alverdy JC. 2017. *De novo* synthesis of phosphorylated triblock copolymers with pathogen virulence-suppressing properties that prevent infection-related mortality. *ACS Biomater Sci Eng* 3:2076–2085. <https://doi.org/10.1021/acsbmaterials.7b00373>.
33. Zaborin A, Smith D, Garfield K, Quensen J, Shakhsheer B, Kade M, Tirrell M, Tiedje J, Gilbert JA, Zaborina O, Alverdy JC. 2014. Membership and behavior of ultra-low-diversity pathogen communities present in the gut of humans during prolonged critical illness. *mBio* 5:e01361-14–e01314. <https://doi.org/10.1128/mBio.01361-14>.
34. Wiegierinck M, Hyoju SK, Mao J, Zaborin A, Adriaansens C, Salzman E, Hyman NH, Zaborina O, van Goor H, Alverdy JC. 2018. Novel *de novo* synthesized phosphate carrier compound ABA-PEG20k-Pi20 suppresses collagenase production in *Enterococcus faecalis* and prevents colonic anastomotic leak in an experimental model. *Br J Surg* 105:1368–1376. <https://doi.org/10.1002/bjs.10859>.
35. Nichols D, Pimentel MB, Borges FTP, Hyoju SK, Teymour F, Hong SH, Zaborina OY, Alverdy JC, Papavasiliou G. 2019. Sustained release of phosphates from hydrogel nanoparticles suppresses bacterial collagenase and biofilm formation *in vitro*. *Front Bioeng Biotechnol* 7:153. <https://doi.org/10.3389/fbioe.2019.00153>.
36. Hyoju SK, Klabbers RE, Aaron M, Krezalek MA, Zaborin A, Wiegierinck M, Hyman NH, Zaborina O, Van Goor H, Alverdy JC. 2018. Oral polyphosphate suppresses bacterial collagenase production and prevents anastomotic leak due to *Serratia marcescens* and *Pseudomonas aeruginosa*. *Ann Surg* 267:1112–1118. <https://doi.org/10.1097/SLA.0000000000002167>.
37. O’Neil J. 2016. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.
38. Taylor J, Hafner M, Yerushalmi E, Smith R, Bellasio J, Vardavas R, Bienkowska T, Rubin J. 2018. Estimating the economic costs of antimicrobial resistance. Rand Corporation. https://www.rand.org/pubs/research_reports/RR911.html.
39. Ardal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, Sumpradit N. 2020. Antibiotic development - economic, regulatory and societal challenges. *Nat Rev Microbiol* 18:267–274. <https://doi.org/10.1038/s41579-019-0293-3>.
40. Ventola CL. 2015. The antibiotic resistance crisis: part 1: causes and threats. *PT* 40:277–283.
41. WHO. 2014. Antimicrobial Resistance: Global report on Surveillance. https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_engpdf?sessionid=D6567BD288AB09C8AE4C5D5F85608685?sequence=1.
42. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavalieri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 18:318–327. <https://www.sciencedirect.com/science/article/pii/S1473309917307533?via%3Dihub>.
43. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. 2008. The biology and future prospects of antivirulence therapies. *Nat Rev Microbiol* 6:17–27. <https://doi.org/10.1038/nrmicro1818>.
44. Bjarnsholt T, Ciofu O, Molin S, Givskov M, Hoiby N. 2013. Applying insights from biofilm biology to drug development - can a new approach be developed? *Nat Rev Drug Discov* 12:791–808. <https://doi.org/10.1038/nrd4000>.
45. Allen RC, Popat R, Diggle SP, Brown SP. 2014. Targeting virulence: can we make evolution-proof drugs? *Nat Rev Microbiol* 12:300–308. <https://doi.org/10.1038/nrmicro3232>.
46. Krell T, Matilla MA. 2022. Antimicrobial resistance: progress and challenges in antibiotic discovery and anti-infective therapy. *Microb Biotechnol* 15:70–78. <https://doi.org/10.1111/1751-7915.13945>.
47. Chadha J, Harjai K, Chhibber S. 2022. Revisiting the virulence hallmarks of *Pseudomonas aeruginosa*: a chronicle through the perspective of quorum sensing. *Environ Microbiol* 24:2630–2656. <https://doi.org/10.1111/1462-2920.15784>.
48. Winsor GL, Griffiths EJ, Lo R, Dhillon BK, Shay JA, Brinkman FS. 2016. Enhanced annotations and features for comparing thousands of *Pseudomonas* genomes in the *Pseudomonas* genome database. *Nucleic Acids Res* 44:D646–53. <https://doi.org/10.1093/nar/gkv1227>.
49. Otero-Asman JR, Quesada JM, Jim KK, Ocampo-Sosa A, Civantos C, Bitter W, Llamas MA. 2020. The extracytoplasmic function sigma factor σ (Vrel) is active during infection and contributes to phosphate starvation-induced virulence of *Pseudomonas aeruginosa*. *Sci Rep* 10:3139. <https://doi.org/10.1038/s41598-020-60197-x>.
50. Peng YC, Lu C, Li G, Eichenbaum Z, Lu CD. 2017. Induction of the *pho* regulon and polyphosphate synthesis against spermine stress in *Pseudomonas aeruginosa*. *Mol Microbiol* 104:1037–1051. <https://doi.org/10.1111/mmi.13678>.
51. Modi N, Ganguly S, Bárcena-Urribarri I, Benz R, van den Berg B, Kleinekathöfer U. 2015. Structure, dynamics, and substrate specificity of the OprO porin from *Pseudomonas aeruginosa*. *Biophys J* 109:1429–1438. <https://doi.org/10.1016/j.bpj.2015.07.035>.
52. Chevalier S, Bouffartigues E, Bodilis J, Maillot O, Lesouhaitier O, Feuilloley MGJ, Orange N, Dufour A, Cornelis P. 2017. Structure, function and regulation of *Pseudomonas aeruginosa* porins. *FEMS Microbiol Rev* 41:698–722. <https://doi.org/10.1093/femsre/fux020>.
53. Chugani S, Greenberg EP. 2007. The influence of human respiratory epithelia on *Pseudomonas aeruginosa* gene expression. *Microb Pathog* 42: 29–35. <https://doi.org/10.1016/j.micpath.2006.10.004>.
54. Stasi R, Neves HI, Spira B. 2019. Phosphate uptake by the phosphonate transport system PhnCDE. *BMC Microbiol* 19:79. <https://doi.org/10.1186/s12866-019-1445-3>.
55. Rapisarda C, Tassinari M, Gubellini F, Fronzes R. 2018. Using cryo-EM to investigate bacterial secretion systems. *Annu Rev Microbiol* 72:231–254. <https://doi.org/10.1146/annurev-micro-090817-062702>.
56. Filloux A. 2011. Protein secretion systems in *Pseudomonas aeruginosa*: an essay on diversity, evolution, and function. *Front Microbiol* 2:155. <https://doi.org/10.3389/fmicb.2011.00155>.
57. Peters JE, Park SJ, Darzins A, Freck LC, Saulnier JM, Wallach JM, Galloway DR. 1992. Further studies on *Pseudomonas aeruginosa* LasA: analysis of specificity. *Mol Microbiol* 6:1155–1162. <https://doi.org/10.1111/j.1365-2958.1992.tb01554.x>.
58. Kieley CM, Sherratt MJ, Shuttleworth CA. 2002. Elastic fibres. *J Cell Sci* 115:2817–2828. <https://doi.org/10.1242/jcs.115.14.2817>.

59. Cowell BA, Twining SS, Hobden JA, Kwong MSF, Fleiszig SMJ. 2003. Mutation of *lasA* and *lasB* reduces *Pseudomonas aeruginosa* invasion of epithelial cells. *Microbiology (Reading)* 149:2291–2299. <https://doi.org/10.1099/mic.0.26280-0>.
60. Tan X, Cheng X, Hu M, Zhang Y, Jia A, Zhou J, Zhu G. 2021. Transcriptional analysis and target genes discovery of *Pseudomonas aeruginosa* biofilm developed *ex vivo* chronic wound model. *AMB Express* 11:157–157. <https://doi.org/10.1186/s13568-021-01317-2>.
61. Ball G, Durand E, Lazdunski A, Filloux A. 2002. A novel type II secretion system in *Pseudomonas aeruginosa*. *Mol Microbiol* 43:475–485. <https://doi.org/10.1046/j.1365-2958.2002.02759.x>.
62. Filloux A, Michel G, Bally M. 1998. GSP-dependent protein secretion in gram-negative bacteria: the Xcp system of *Pseudomonas aeruginosa*. *FEMS Microbiol Rev* 22:177–198. <https://doi.org/10.1111/j.1574-6976.1998.tb00366.x>.
63. Lewenza S, Charron-Mazenod L, Afroj S, van Tilburg Bernardes E. 2017. Hyperbiofilm phenotype of *Pseudomonas aeruginosa* defective for the PlcB and PlcN secreted phospholipases. *Can J Microbiol* 63:780–787. <https://doi.org/10.1139/cjm-2017-0244>.
64. Wilton M, Halverson TWR, Charron-Mazenod L, Parkins MD, Lewenza S. 2018. Secreted phosphatase and deoxyribonuclease are required by *Pseudomonas aeruginosa* to defend against neutrophil extracellular traps. *Infect Immun* 86:e00403-18. <https://doi.org/10.1128/IAI.00403-18>.
65. Filloux A, Hachani A, Blevès S. 2008. The bacterial type VI secretion machine: yet another player for protein transport across membranes. *Microbiology (Reading)* 154:1570–1583. <https://doi.org/10.1099/mic.0.2008/016840-0>.
66. Sana TG, Berni B, Blevès S. 2016. The T6SSs of *Pseudomonas aeruginosa* Strain PAO1 and Their Effectors: beyond Bacterial-Cell Targeting. *Front Cell Infect Microbiol* 6:61. <https://doi.org/10.3389/fcimb.2016.00061>.
67. Ueda A, Wood TK. 2009. Connecting quorum sensing, c-di-GMP, pel polysaccharide, and biofilm formation in *Pseudomonas aeruginosa* through tyrosine phosphatase TpbA (PA3885). *PLoS Pathog* 5:e1000483. <https://doi.org/10.1371/journal.ppat.1000483>.
68. Pu M, Wood TK. 2010. Tyrosine phosphatase TpbA controls rugose colony formation in *Pseudomonas aeruginosa* by dephosphorylating diguanylate cyclase TpbB. *Biochem Biophys Res Commun* 402:351–355. <https://doi.org/10.1016/j.bbrc.2010.10.032>.
69. Domenech CE, Otero LH, Beassoni PR, Lisa AT. 2011. Phosphorylcholine Phosphatase: a Peculiar Enzyme of *Pseudomonas aeruginosa*. *Enzyme Res* 2011:561841. <https://doi.org/10.4061/2011/561841>.
70. Ostroff RM, Wretling B, Vasil ML. 1989. Mutations in the hemolytic-phospholipase C operon result in decreased virulence of *Pseudomonas aeruginosa* PAO1 grown under phosphate-limiting conditions. *Infect Immun* 57:1369–1373. <https://doi.org/10.1128/iai.57.5.1369-1373.1989>.
71. Cota-Gomez A, Vasil AI, Kadurugamuwa J, Beveridge TJ, Schweizer HP, Vasil ML. 1997. PlcR1 and PlcR2 are putative calcium-binding proteins required for secretion of the hemolytic phospholipase C of *Pseudomonas aeruginosa*. *Infect Immun* 65:2904–2913. <https://doi.org/10.1128/iai.65.7.2904-2913.1997>.
72. Vilaplana L, Marco MP. 2020. Phenazines as potential biomarkers of *Pseudomonas aeruginosa* infections: synthesis regulation, pathogenesis and analytical methods for their detection. *Anal Bioanal Chem* 412:5897–5912. <https://doi.org/10.1007/s00216-020-02696-4>.
73. Biswas L, Götz F. 2021. Molecular Mechanisms of *Staphylococcus* and *Pseudomonas* Interactions in Cystic Fibrosis. *Front Cell Infect Microbiol* 11:824042. <https://doi.org/10.3389/fcimb.2021.824042>.
74. Hall S, McDermott C, Anoopkumar-Dukie S, McFarland AJ, Forbes A, Perkins AV, Davey AK, Chess-Williams R, Kiefel MJ, Arora D, Grant GD. 2016. Cellular Effects of Pyocyanin, a Secreted Virulence Factor of *Pseudomonas aeruginosa*. *Toxins* 8:236. <https://doi.org/10.3390/toxins8080236>.
75. Matilla MA, Martin-Mora D, Gavira JA, Krell T. 2021. *Pseudomonas aeruginosa* as a model to study chemosensory pathway signaling. *Microbiol Mol Biol Rev* 85:e00151-20. <https://doi.org/10.1128/MMBR.00151-20>.
76. Garcia-Fontana C, Vilchez J, Gonzalez-Requena M, Gonzalez-Lopez J, Krell T, Matilla MA, Manzanera M. 2019. The involvement of McpB chemoreceptor from *Pseudomonas aeruginosa* PAO1 in virulence. *Sci Rep* 9:13166. <https://doi.org/10.1038/s41598-019-49697-7>.
77. Garvis S, Munder A, Ball G, de Bentzmann S, Wiehlmann L, Ewbank JJ, Tummler B, Filloux A. 2009. *Caenorhabditis elegans* semi-automated liquid screen reveals a specialized role for the chemotaxis gene *cheB2* in *Pseudomonas aeruginosa* virulence. *PLoS Pathog* 5:e1000540. <https://doi.org/10.1371/journal.ppat.1000540>.
78. Lee J, Zhang L. 2015. The hierarchy quorum sensing network in *Pseudomonas aeruginosa*. *Protein Cell* 6:26–41. <https://doi.org/10.1007/s13238-014-0100-x>.
79. Schuster M, Lostrich CP, Ogi T, Greenberg EP. 2003. Identification, timing, and signal specificity of *Pseudomonas aeruginosa* quorum-controlled genes: a transcriptome analysis. *J Bacteriol* 185:2066–2079. <https://doi.org/10.1128/JB.185.7.2066-2079.2003>.
80. Jensen V, Löns D, Zaoui C, Bredenbruch F, Meissner A, Dieterich G, Münch R, Häussler S. 2006. RhlR expression in *Pseudomonas aeruginosa* is modulated by the *Pseudomonas* quinolone signal via PhoB-dependent and -independent pathways. *J Bacteriol* 188:8601–8606. <https://doi.org/10.1128/JB.01378-06>.
81. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Hoiby N, Moskowitz SM. 2013. Polymyxin resistance of *Pseudomonas aeruginosa* *phoQ* mutants is dependent on additional two-component regulatory systems. *Antimicrob Agents Chemother* 57:2204–2215. <https://doi.org/10.1128/AAC.02353-12>.
82. Kaihama GH, Breda LCD, de Almeida JRF, de Oliveira Pereira T, Nicastro GG, Boechat AL, de Almeida SR, Baldini RL. 2017. The atypical response regulator *atvr* is a new player in *Pseudomonas aeruginosa* response to hypoxia and virulence. *Infect Immun* 85:e00207-17. <https://doi.org/10.1128/IAI.00207-17>.
83. Petrova OE, Sauer K. 2009. A novel signaling network essential for regulating *Pseudomonas aeruginosa* biofilm development. *PLoS Pathog* 5:e1000668. <https://doi.org/10.1371/journal.ppat.1000668>.
84. Cao Q, Yang N, Wang Y, Xu C, Zhang X, Fan K, Chen F, Liang H, Zhang Y, Deng X, Feng Y, Yang CG, Wu M, Bae T, Lan L. 2020. Mutation-induced remodeling of the BfmR5 two-component system in *Pseudomonas aeruginosa* clinical isolates. *Sci Signal* 13:eaaz1529. <https://doi.org/10.1126/scisignal.aaz1529>.
85. Chuanchuen R, Gaynor JB, Karkhoff-Schweizer R, Schweizer HP. 2005. Molecular characterization of MexL, the transcriptional repressor of the *mexJK* multidrug efflux operon in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 49:1844–1851. <https://doi.org/10.1128/AAC.49.5.1844-1851.2005>.
86. Juarez P, Jeannot K, Plésiat P, Llanes C. 2017. Toxic electrophiles induce expression of the multidrug efflux Pump MexEF-OprN in *Pseudomonas aeruginosa* through a novel transcriptional regulator, CmrA. *Antimicrob Agents Chemother* 61:e00585-17. <https://doi.org/10.1128/AAC.00585-17>.
87. Wang F, He Q, Yin J, Xu S, Hu W, Gu L. 2018. BrIR from *Pseudomonas aeruginosa* is a receptor for both cyclic di-GMP and pyocyanin. *Nat Commun* 9:2563. <https://doi.org/10.1038/s41467-018-05004-y>.
88. Jones CJ, Ryder CR, Mann EE, Wozniak DJ. 2013. AmrZ modulates *Pseudomonas aeruginosa* biofilm architecture by directly repressing transcription of the *psl* operon. *J Bacteriol* 195:1637–1644. <https://doi.org/10.1128/JB.02190-12>.
89. Xu A, Zhang M, Du W, Wang D, Ma LZ. 2021. A molecular mechanism for how sigma factor AlgT and transcriptional regulator AmrZ inhibit twitching motility in *Pseudomonas aeruginosa*. *Environ Microbiol* 23:572–587. <https://doi.org/10.1111/1462-2920.14985>.
90. Allsopp LP, Wood TE, Howard SA, Maggiorelli F, Nolan LM, Wettstadt S, Filloux A. 2017. RsmA and AmrZ orchestrate the assembly of all three type VI secretion systems in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 114:7707–7712. <https://doi.org/10.1073/pnas.1700286114>.
91. Potvin E, Sanschagrin F, Levesque RC. 2008. Sigma factors in *Pseudomonas aeruginosa*. *FEMS Microbiol Rev* 32:38–55. <https://doi.org/10.1111/j.1574-6976.2007.00092.x>.
92. Xu L, Xin L, Zeng Y, Yam JK, Ding Y, Venkataramani P, Cheang QW, Yang X, Tang X, Zhang LH, Chiam KH, Yang L, Liang ZX. 2016. A cyclic di-GMP-binding adaptor protein interacts with a chemotaxis methyltransferase to control flagellar motor switching. *Sci Signal* 9:ra102. <https://doi.org/10.1126/scisignal.aaf7584>.
93. Miklavić Š, Kogovšek P, Hodnik V, Korošec J, Kládnik A, Anderluh G, Gutierrez-Aguirre I, Maček P, Butala M. 2015. The *Pseudomonas aeruginosa* RhlR-controlled aegerolysin RalU is a low-affinity rhamnolipid-binding protein. *FEMS Microbiol Lett* 362:fnv069.
94. Rao J, DiGiandomenico A, Artamonov M, Leitinger N, Amin AR, Goldberg JB. 2011. Host derived inflammatory phospholipids regulate *rahU* (PAO122) gene, protein, and biofilm formation in *Pseudomonas aeruginosa*. *Cell Immunol* 270:95–102. <https://doi.org/10.1016/j.cellimm.2011.04.011>.
95. Rao J, Elliott MR, Leitinger N, Jensen RV, Goldberg JB, Amin AR. 2011. RalU: an inducible and functionally pleiotropic protein in *Pseudomonas*

- aeruginosa* modulates innate immunity and inflammation in host cells. *Cell Immunol* 270:103–113. <https://doi.org/10.1016/j.cellimm.2011.05.012>.
96. Fernández L, Breidenstein EB, Song D, Hancock RE. 2012. Role of intracellular proteases in the antibiotic resistance, motility, and biofilm formation of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 56: 1128–1132. <https://doi.org/10.1128/AAC.05336-11>.
 97. Abdel-Mawgoud AM, Lépine F, Déziel E. 2010. Rhamnolipids: diversity of structures, microbial origins and roles. *Appl Microbiol Biotechnol* 86: 1323–1336. <https://doi.org/10.1007/s00253-010-2498-2>.
 98. Moskowitz SM, Ernst RK, Miller SI. 2004. PmrAB, a two-component regulatory system of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. *J Bacteriol* 186:575–579. <https://doi.org/10.1128/JB.186.2.575-579.2004>.
 99. Lee JY, Chung ES, Na IY, Kim H, Shin D, Ko KS. 2014. Development of colistin resistance in *pmrA*-, *phoP*-, *parR*- and *cprR*-inactivated mutants of *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 69:2966–2971. <https://doi.org/10.1093/jac/dku238>.
 100. McCarthy RR, Mazon-Moya MJ, Moscoso JA, Hao Y, Lam JS, Bordi C, Mostowy S, Filloux A. 2017. Cyclic-di-GMP regulates lipopolysaccharide modification and contributes to *Pseudomonas aeruginosa* immune evasion. *Nat Microbiol* 2:17027. <https://doi.org/10.1038/nmicrobiol.2017.27>.
 101. Srivastava D, Seo J, Rimal B, Kim SJ, Zhen S, Darwin AJ. 2018. A Proteolytic Complex Targets Multiple Cell Wall Hydrolases in *Pseudomonas aeruginosa*. *mBio* 9:e00972-18. <https://doi.org/10.1128/mBio.00972-18>.
 102. Seo J, Darwin AJ. 2013. The *Pseudomonas aeruginosa* periplasmic protease CtpA can affect systems that impact its ability to mount both acute and chronic infections. *Infect Immun* 81:4561–4570. <https://doi.org/10.1128/IAI.01035-13>.
 103. Harrison LB, Fowler RC, Abdalhamid B, Selmecki A, Hanson ND. 2019. IptG contributes to changes in membrane permeability and the emergence of multidrug hypersusceptibility in a cystic fibrosis isolate of *Pseudomonas aeruginosa*. *Microbiologyopen* 8:e844. <https://doi.org/10.1002/mbo3.844>.
 104. McClean KH, Winson MK, Fish L, Taylor A, Chhabra SR, Camara M, Daykin M, Lamb JH, Swift S, Bycroft BW, Stewart G, Williams P. 1997. Quorum sensing and *Chromobacterium violaceum*: exploitation of violacein production and inhibition for the detection of N-acylhomoserine lactones. *Microbiology* 143:3703–3711. <https://doi.org/10.1099/00221287-143-12-3703>.
 105. Bonn F, Bartel J, Buttner K, Hecker M, Otto A, Becher D. 2014. Picking vanished proteins from the void: how to collect and ship/share extremely dilute proteins in a reproducible and highly efficient manner. *Anal Chem* 86:7421–7427. <https://doi.org/10.1021/ac501189j>.
 106. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. 2011. Global quantification of mammalian gene expression control. *Nature* 473:337–342. <https://doi.org/10.1038/nature10098>.
 107. Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* 26:1367–1372. <https://doi.org/10.1038/nbt.1511>.
 108. Gu Z, Eils R, Schlesner M. 2016. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* 32:2847–2849. <https://doi.org/10.1093/bioinformatics/btw313>.
 109. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. 2016. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res* 44:D457–62. <https://doi.org/10.1093/nar/gkv1070>.
 110. Vizcaino JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, Xu QW, Wang R, Hermjakob H. 2016. 2016 update of the PRIDE database and its related tools. *Nucleic Acids Res* 44:11033. <https://doi.org/10.1093/nar/gkw880>.
 111. Clarke DM, Loo TW, Gillam S, Bragg PD. 1986. Nucleotide sequence of the *pntA* and *pntB* genes encoding the pyridine nucleotide transhydrogenase of *Escherichia coli*. *Eur J Biochem* 158:647–653. <https://doi.org/10.1111/j.1432-1033.1986.tb09802.x>.
 112. Jones CJ, Newsom D, Kelly B, Irie Y, Jennings LK, Xu B, Limoli DH, Harrison JJ, Parsek MR, White P, Wozniak DJ. 2014. ChIP-Seq and RNA-Seq reveal an AmrZ-mediated mechanism for cyclic di-GMP synthesis and biofilm development by *Pseudomonas aeruginosa*. *PLoS Pathog* 10: e1003984. <https://doi.org/10.1371/journal.ppat.1003984>.
 113. Intile PJ, Balzer GJ, Wolfgang MC, Yahr TL. 2015. The RNA helicase DeaD stimulates ExsA translation to promote expression of the *Pseudomonas aeruginosa* type III secretion system. *J Bacteriol* 197:2664–2674. <https://doi.org/10.1128/JB.00231-15>.
 114. Salusso A, Raimunda D. 2017. Defining the roles of the cation diffusion facilitators in Fe⁽²⁺⁾/Zn⁽²⁺⁾ homeostasis and establishment of their participation in virulence in *Pseudomonas aeruginosa*. *Front Cell Infect Microbiol* 7:84. <https://doi.org/10.3389/fcimb.2017.00084>.
 115. Ishige K, Zhang H, Kornberg A. 2002. Polyphosphate kinase (PPK2), a potent, polyphosphate-driven generator of GTP. *Proc Natl Acad Sci U S A* 99:16684–16688. <https://doi.org/10.1073/pnas.262652999>.
 116. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH. 2003. Microarray analysis of *Pseudomonas aeruginosa* quorum-sensing regulons: effects of growth phase and environment. *J Bacteriol* 185:2080–2095. <https://doi.org/10.1128/JB.185.7.2080-2095.2003>.
 117. Mavrodi DV, Bonsall RF, Delaney SM, Soule MJ, Phillips G, Thomashow LS. 2001. Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 183:6454–6465. <https://doi.org/10.1128/JB.183.21.6454-6465.2001>.
 118. Siehnel RJ, Worobec EA, Hancock RE. 1988. Regulation of components of the *Pseudomonas aeruginosa* phosphate-starvation-inducible regulon in *Escherichia coli*. *Mol Microbiol* 2:347–352. <https://doi.org/10.1111/j.1365-2958.1988.tb00038.x>.
 119. Faure LM, Garvis S, de Bentzmann S, Bigot S. 2014. Characterization of a novel two-partner secretion system implicated in the virulence of *Pseudomonas aeruginosa*. *Microbiology* 160:1940–1952. <https://doi.org/10.1099/mic.0.079616-0>.
 120. Faure LM, Llamas MA, Bastiaansen KC, de Bentzmann S, Bigot S. 2013. Phosphate starvation relayed by PhoB activates the expression of the *Pseudomonas aeruginosa* σ^{Vrel} ECF factor and its target genes. *Microbiology* 159:1315–1327. <https://doi.org/10.1099/mic.0.067645-0>.
 121. Quesada JM, Otero-Asman JR, Bastiaansen KC, Civantos C, Llamas MA. 2016. The activity of the *Pseudomonas aeruginosa* virulence regulator σ^{Vrel} is modulated by the anti- σ factor VreR and the transcription factor PhoB. *Front Microbiol* 7:1159. <https://doi.org/10.3389/fmicb.2016.01159>.